Denosumab

Overview

4.7 out of 5 (23 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Sep 2023

Last Review Date

28 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Denosumab, a bone anti-resorptive medication, treats osteoporosis and various bone-related disorders. Its FDA-approved applications span a spectrum of conditions, encompassing the prevention of skeletal-related events such as bone pain and fractures arising secondary to multiple myeloma or bone metastases from solid tumors, giant cell tumors of the bone, hypercalcemia of malignancy, osteoporosis in postmenopausal women at high fracture risk, and men facing an increased risk of fracture due to osteoporosis or glucocorticoid-induced bone loss. This activity focuses on elucidating denosumab's mechanism of action, adverse event profile, toxicity considerations, optimal dosing strategies, pharmacodynamics, and the essential parameters for diligent monitoring. Interprofessional team members will increase their understanding of when denosumab therapy is indicated, thereby facilitating optimal patient outcomes.

Participants gain comprehension of denosumab's pivotal role as a total human IgG2 monoclonal antibody. By selectively binding to the receptor activator of the NF kappa B ligand (RANKL), denosumab competently inhibits its interaction with the NF kappa B receptor activator (RANK). This inhibition forms the crux of its therapeutic efficacy in preventing bone resorption and mitigating associated risks. The content strategically navigates through pertinent aspects, empowering healthcare professionals to make informed decisions and contribute effectively to patient care within denosumab therapy.


UAN: JA4008338-0000-23-5215-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify the appropriate indications for denosumab therapy in treating osteoporosis, metastatic bone disease, certain bone tumors, and treatment-induced bone loss.

  • Screen patients for eligibility and assess their suitability for denosumab therapy, considering factors such as medical history, concurrent medications, and potential contraindications.

  • Apply knowledge of the adverse effects of denosumab and proactively manage and monitor potential complications.

  • Implement effective communication with patients about denosumab therapy's benefits, risks, and expectations, ensuring informed and shared decision-making.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.00 ACPE credit(s). (UAN: JA4008338-0000-23-5215-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Joseph B. on 10/30/2021

on 3/27/2022

Shannon j. on 7/25/2022

Clifford A. on 8/10/2022

Mary Y. on 8/28/2022

efstathia c. on 12/26/2022

Peter S. on 1/4/2023

Przemyslaw L. on 3/15/2023

James l. on 4/1/2023

Mary Y. on 4/10/2023

Sydney d. on 6/30/2023

Ashvini S. on 6/23/2023

Ronald D. on 7/13/2023

Dennis R. on 7/14/2023

Edgardo R. on 7/22/2023

Mohammad J. on 7/24/2023

Larry S. on 8/3/2023

None.

Richard P. on 9/4/2023

John T. on 9/22/2023

Erika G. on 1/16/2024

John L. on 2/26/2024

Gurdeep C. on 3/6/2024

Mark A. on 3/25/2024

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

Single Activity

Take this single activity

$29 1 activity

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user